Adtran expands Oscilloquartz PNT platform for enhanced protection of critical timing networks
16.5.2023 15:00:00 EEST | Business Wire | Press release
Adtran today launched a major upgrade of its Oscilloquartz aPNT+™ technology suite, bringing new levels of resilience to critical network infrastructure that relies on position, navigation and timing (PNT) services. With enhancements to its core, edge and access synchronization solutions, the portfolio provides operators of telecommunications, financial networks, power grids, defense infrastructure and more with the best available protection against GNSS vulnerabilities and cyberattacks. Adtran’s timing technology now leverages more sources of accurate and reliable timing and features new capabilities to detect disturbances and assure vital PNT services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230512005309/en/
Adtran’s Oscilloquartz aPNT+™ platform is a vital tool for keeping critical infrastructure safe and online. (Photo: Business Wire)
“From 5G connectivity to air traffic control, accurate and reliable PNT services are crucial for the safety, efficiency and optimal performance of a wide range of modern applications. That’s why the enhancements we’ve made to our aPNT+™ platform are so significant. These include improved jamming and spoofing detection using a unique, highly advanced, dedicated algorithm to ensure maximum resilience against any intentional or unintentional interference,” said Igal Pinhasov, VP of product line management at Oscilloquartz, Adtran. “Our upgraded portfolio is a significant step up for critical network timing. It provides unparalleled precision and reliability even in the most challenging environments, including situations where GNSS is disrupted for extended periods.”
Adtran’s OSA 5401 and 5405 access network synchronization solutions now feature the same advanced jamming and spoofing detection capabilities as its core and edge products. Additionally, the OSA 5405-MB, a compact and integrated outdoor multi-band GNSS receiver and PTP grandmaster, has been upgraded with improved multi-band capabilities. As well as satellite constellations, including GPS, GLONASS, BeiDou and GALILEO, it now supports the Indian Regional Navigation Satellite System (IRNSS). This is critical for mobile network operators in the subcontinent, as the Indian government has ruled that smartphones must be compatible with the country’s home-grown GNSS system. Furthermore, the solution now utilizes a combination of L1 and L5 band signals to better mitigate disruption caused by environmental factors.
“Enhanced NTP functionality is another feature that makes our upgraded aPNT+™ platform even more powerful. Our standalone NTP servers can now support up to 500,000 transactions per second, providing unique NTP performance. This level of transaction handling is a significant advantage against DDoS attacks,” commented Gil Biran, GM of Oscilloquartz, Adtran. “Our core and edge grandmaster clocks are also more resilient than ever. With our multi-source ePRTC combiner, they can leverage up to five independent timing sources, which can include up to three high-performance optical cesium atomic clocks, to create a single super-resilient and highly reliable clock source. Customers can select from GNSS constellations, PTP inputs, and alternative PNT sources such as STL, which uses low Earth orbit satellites, or the terrestrial-based eLORAN. Both offer extra protection against jamming and spoofing attacks while extending the 100nsec holdover period.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of ADVA. Find more at Adtran, LinkedIn and Twitter.
Published by
ADTRAN Holdings, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230512005309/en/
Contact information
For media
Gareth Spence
+44 1904 699 358
public-relations@adva.com
For investors
Steven Williams
+49 89 890 665 918
investor@adtran.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom